Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F7CR3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,467
Award facts
- Contract value 100% obligated
- $12,466.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,466.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 26, 2026, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This non-set-aside competitive award is set to complete by January 27, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a task order issued under AmerisourceBergen's parent company, Cencora, Inc.'s, comprehensive Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor for federal medical procurement, particularly supplying military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. Dupixent (dupilumab) is a biologic medication primarily used to treat atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, representing the type of specialty pharmaceutical products the company routinely delivers under its federal contracts. The parent company, Cencora, Inc., maintains an extensive portfolio of federal contracts encompassing diverse therapeutic domains and competes successfully on a full and open basis across government healthcare agencies without set-aside restrictions.
Quick answers
Who was awarded contract SPE2DR26F7CR3?
SPE2DR26F7CR3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26F7CR3 worth?
The government has obligated $12,467 on SPE2DR26F7CR3.
Is contract SPE2DR26F7CR3 an order under another contract?
Yes. SPE2DR26F7CR3 is a delivery order under SPE2DR25D3504, an indefinite delivery contract.
Was contract SPE2DR26F7CR3 competed?
The extent of competition for SPE2DR26F7CR3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award